India

India, in the Asian subcontinent is the world’s fourth largest producer of pharmaceuticals, and is thought as one of the most promising biotech markets in the world. Several important steps...

The Top 100 Pharmaceutical Companies

The Top 100 Pharmaceutical Companies, determined by total sales in 2011 - see below for 2010 and  2009: They are listed in descending order with the sales in 2011 in $ million; Pfizer ...

Mylan in collaboration with Biocon for insulin marketing

Mylan, top pharmaceutical company, in collaboration with Biocon for an exclusive strategic alliance on the development and commercialization of generic versions of three insulin analog products. Under...

Mylan and Biocon to partner on insulin products

Generics giant Mylan announced on 13 February 2013 that it had entered into an agreement with India-based Biocon to develop and market Biocon’s biosimilar version of three insulin analogue products.

India approves Biocon's anti-CD6 mAb

Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) said India's Drugs Controller General of India (DCGI) approved Alzumab itolizumab to treat chronic plaque psoriasis. The company plans to launch the humanized IgG1...

Mylan, Biocon in insulin biosimilars deal

Mylan Inc. (NASDAQ:MYL) partnered with Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) to develop and commercialize Biocon's biosimilar versions of three insulin analog products -- glargine, aspart and lispro....

BMS receives option for Biocon's oral insulin analog

Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) granted Bristol-Myers Squibb Co. (NYSE:BMY) an exclusive option to license worldwide rights outside of India to diabetes product IN-105. Biocon will further charac...

Bristol-Myers Squibb signs option for Biocon's oral insulin drug candidate

Bangalore, India-based biotechnology firm Biocon (BSE: 532523) has entered into an option agreement with US drug major Bristol-Myers Squibb (NYSE: BMY) for Biocon's IN-105, a prandial oral insulin pro...

GE Capital to invest in Biocon's Syngene

Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) said General Electric Co. (NYSE:GE) will invest Rs1.2 billion ($22.8 million) to acquire a 7.69% stake in Biocon's research services subsidiary Syngene Internation...

Biocon: Company profile

Website: Biocon Headquarters: Bengaluru, India SEC Link: Biocon Subsidiary Companies: Biocon Group CIMAB SA Top BigBiotech ranking*: 27 *Ranking based on reported global biotech sales for year endin...

A novel one-pot de-blocking and conjugation reaction step leads to process intensification in the manufacture of PEGylated insulin IN-105.

Bio-catalytic in vitro multistep reactions can be combined in a single step in one pot by optimizing multistep reactions under identical reaction condition. Using this analogy, the process of making P...

Prodrug Design to Improve Pharmacokinetic and Drug Delivery Properties: Challenges to the Discovery Scientists.

The prodrug design is a versatile, powerful method that can be applied to a wide range of parent drug molecules, administration routes, and formulations. Clinically, the majority of prodrugs are used...

Synthesis and biological property of some novel 1,3,4-oxadiazoles.

A series of biphenyl-1,3,4-oxadiazoles namely 5-[substituted-(1,1'-biphenyl)-3-yl]-1,3,4-oxadiazole-2(3H)-thiones and its S-alkyl derivatives have been synthesized by multi step organic synthesis invo...

Development and validation of LC-MS/MS method for the estimation of β-hydroxy-β-methylbutyrate in rat plasma and its application to pharmacokinetic studies.

A simple, sensitive and specific high-performance liquid chromatography mass spectrometry (LC-MS/MS) method was developed and validated for the quantification of β-hydroxy-β-methyl butyrate (HMB) in...

Accuracy of post-void residual urine volume measurement using a portable ultrasound bladder scanner with real-time pre-scan imaging.

AIMS: To evaluate whether the bladder scanner with real-time pre-scan imaging (RPI) is superior to the conventional bladder scanner in measuring post-void residual urine (PVR) volume. METHODS: Sixty-s...